Premium
Preoperative oral granisetron prevents postoperative nausea and vomiting
Author(s) -
Fujii Y.,
Tanaka H.,
Toyooka H.
Publication year - 1998
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1998.tb05297.x
Subject(s) - granisetron , medicine , placebo , postoperative nausea and vomiting , anesthesia , nausea , adverse effect , vomiting , antiemetic , incidence (geometry) , general anaesthesia , surgery , physics , alternative medicine , pathology , optics
Background: Postoperative nausea and vomiting (PONV) is a commonly observed adverse effect of anaesthesia. This study was designed to evaluate the efficacy of granisetron administered orally for preventing PONV in female patients undergoing major gynaecological surgery. Methods: In a prospective, randomized, placebo‐controlled, double‐blind study, 120 patients received orally either placebo or granisetron (1 mg, 2 mg or 4 mg) (n=30 for each) 1 h before surgery. The same standard general plus regional anaesthetic technique was employed throughout. Postoperatively, during the first 24 h after anaesthesia, the incidence of PONV and adverse events was recorded by nursing staff. Results: The incidence of PONV was 47% with placebo, 37% with granisetron 1 mg, 10% with granisetron 2 mg and 10% with granisetron 4 mg (P<0.05; overall Fisher's exact probability test). No difference in the incidence of adverse events was observed among the groups. Conclusion: Preoperative oral granisetron in a minimum dose of 2 mg is effective for preventing PONV after major gynaecological surgery.